Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/102090
Title: Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Author: Adamo, Barbara
Deal, Allison M.
Burrows, Emily
Geradts, Joseph
Hamilton, Erika
Blackwell, Kimberly L,
Livasy, Chad
Fritchie, Karen
Prat Aparicio, Aleix
Harrell, J.Chuck
Ewend, Matthew G.
Carey, Lisa A.
Miller, C. Ryan
Anders, Careu K.
Keywords: Càncer de mama
Càncer de cap
Oncogens
Teràpia genètica
Marcadors bioquímics
Breast cancer
Head cancer
Oncogenes
Gene therapy
Biochemical markers
Issue Date: 1-Dec-2011
Publisher: BioMed Central
Abstract: Activation status of the phosphatidylinositol 3-kinase (PI3K) pathway in breast cancer brain metastases (BCBMs) is largely unknown. We examined expression of phospho(p)-AKT, p-S6, and phosphatase and tensin homologue (PTEN) in BCBMs and their implications for overall survival (OS) and survival after BCBMs. Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs. METHODS: p-AKT, p-S6, and PTEN expression was assessed with immunohistochemistry in 52 BCBMs and 12 matched primary BCs. Subtypes were defined as hormone receptor (HR)+/HER2-, HER2+, and triple-negative (TNBC). Survival analyses were performed by using a Cox model, and survival curves were estimated with the Kaplan-Meier method. RESULTS: Expression of p-AKT and p-S6 and lack of PTEN (PTEN-) was observed in 75%, 69%, and 25% of BCBMs. Concordance between primary BCs and matched BCBMs was 67% for p-AKT, 58% for p-S6, and 83% for PTEN. PTEN- was more common in TNBC compared with HR+/HER2- and HER2+. Expression of p-AKT, p-S6, and PTEN- was not associated with OS or survival after BCBMs (all, P > 0.06). Interestingly, among all patients, PTEN- correlated with shorter time to distant and brain recurrence. Among patients with TNBC, PTEN- in BCBMs was associated with poorer overall survival. CONCLUSIONS: The PI3K pathway is active in most BCBMs regardless of subtype. Inhibition of this pathway represents a promising therapeutic strategy for patients with BCBMs, a group of patients with poor prognosis and limited systemic therapeutic options. Although expression of the PI3K pathway did not correlate with OS and survival after BCBM, PTEN- association with time to recurrence and OS (among patients with TNBC) is worthy of further study.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/bcr3071
It is part of: Breast Cancer Research, 2011, vol. 13, num. 6, p. R125
Related resource: http://dx.doi.org/10.1186/bcr3071
URI: http://hdl.handle.net/2445/102090
ISSN: 1465-5411
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
662598.pdf2 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons